The use of rapid microbiological methods (RMM) is one that has been popular in conferences and the pharma literature for almost 30 years. However, this popularity in the speaking circuit has not been matched by a popularity in proactice for pharma, OTC, personal care products or medical device manufacturers. There are many contributing factors to this slow adoption, but chief among these an over-optimistic expectation for the capabilities and returns on the RMM investiment from a corporate perspective.
Critical to the success of adoption of an RMM in any regulated industry is a clear understanding of not only the real-life capabilities of the different technologies, but also the unambigously stated needs and expectations of the company as a whole for the implementation of that technology. Bringing in a new technology that does not increase corporate income is not in the best interest of the organization.
Let the Microbiology Network assist in determining the true value of the appropriate rapid technology to meet the business needs of your company as a whole. There are many different technologies available for use, let's find the right one together.